Marisa Wexler, MS, senior science writer —

In the brains of people with advanced multiple sclerosis (MS), memory immune cells reside in the brain tissue rather than entering through the bloodstream, a new study suggests. The study, “Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions,” was published…

Healthcare providers should encourage everyone with multiple sclerosis (MS) to engage in regular exercise and keep physically active, new guidelines based on an expert panel convened by the National Multiple Sclerosis Society recommend. They also suggest different types of exercise applicable to people at varying levels of disability.

A portable device that can quickly measure electrical activity in the brain and relay it to doctors via a smartphone app, called the Nurochek system, has been cleared by the United States Food and Drug Administration (FDA) for use as a medical device. Its developer, Headsafe, plans to it…

Belong.Life has launched a free and anonymous social network app to offer support for people with multiple sclerosis (MS), their caregivers, and healthcare professionals. The app is called BelongMS and is now available…

Pain appears to be more intense in people with neuromyelitis optica spectrum disorder (NMOSD) than those with multiple sclerosis (MS), while fatigue levels are comparable between the two disorders, a study reports. Its researchers also link certain types of central nervous system lesions to pain and fatigue in…

The investigational anti-CD20 antibody ublituximab effectively depletes B-cells in people with relapsing forms of multiple sclerosis (MS), reducing the appearance of brain lesions and the risk of relapses, a study into clinical trial results suggests. Findings further suggest that the…

Starting treatment with Ocrevus early can lower almost by half the need for a walking aid in people with relapsing forms of multiple sclerosis (MS) over six years, new analyses of Phase 3 trial data that compared immediate initiation with a two-year delay show. A separate analysis also found…

XRHealth has raised $7 million to expand its telehealth platform, with the goal of providing clinicians and patients with virtual and augmented reality therapy. The funding will also increase access to virtual support groups for people with multiple sclerosis and other diseases. Telehealth broadly refers to the…

The investigational, oral BTK inhibitor SAR442168 can limit the number of new inflammatory brain lesions in people with relapsing forms of multiple sclerosis (MS), results from a Phase 2b clinical trial show. “The results of this study give hope that SAR442168 may become an important…

People with secondary progressive multiple sclerosis (SPMS) who began treatment with Mayzent early and continued its use for years are less likely to experience disability progression than those starting the medication later in their disease course, five-year data from the EXPAND study suggest. Data from this same Phase 3…

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted applications from Genentech to shorten the infusion time for Ocrevus, an approved treatment for multiple sclerosis. If approved, the time to administer Ocrevus will be shortened to a two-hour session, instead…

Sanofi will host an online science session to present results of a Phase 2b clinical trial testing the safety and efficacy of its investigational, oral BTK inhibitor SAR442168 in people with multiple sclerosis (MS). The virtual session, owing to the cancellation of the American Academy…

Treatment with Gilenya (fingolimod) could make people with multiple sclerosis (MS) more vulnerable to the parasitic infection known as cryptosporidiosis, a case report suggests. The report, “Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review,” was published in the jorunal BMC Infectious Diseases. Gilenya…

The Consortium of Multiple Sclerosis Centers (CMSC) and the National Multiple Sclerosis Society have created a new database to track COVID-19 infections in people with multiple sclerosis (MS) and related diseases. The database, called COViMS (COVID-19 Infections in Multiple Sclerosis and Related Diseases),…

People exposed to secondhand cigarette smoke during adolescence may be more likely to develop multiple sclerosis (MS) later in life, a study suggests. The study, “Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis,” was published in the Multiple…

New or worsening headaches are a more common side effect of interferon-beta (IFN-beta) treatment in people with multiple sclerosis (MS) than previously appreciated, a new study suggests. The study, “Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization,” was published in the Journal of Pain Research.

Physical exercise can ease fatigue in people with multiple sclerosis (MS) and potentially benefit them in many other ways, and should be part of rehabilitation programs for patients, a large review study suggests. The study, “The impact of physical exercise on the fatigue symptoms in patients with…

Truxima, a biosimilar of rituximab, is comparable to the originator therapy in terms of effectiveness and safety for treating multiple sclerosis (MS), a new study suggests. Rituximab — marketed as Rituxan in the United States — is an antibody-based therapy that works by killing B-cells, which are immune cells…

EHP-101, a cannabidiol-derived investigational therapy being developed by Emerald Health Pharmaceuticals (EHP) to treat multiple sclerosis (MS), is not a controlled substance in Canada, the company announced. The active ingredient in EHP-101 is a derivative of cannabidiol, abbreviated CBD. This is one of the most well-known active compounds in…

Janssen has submitted an application to the U.S. Food and Drug Administration (FDA) asking for ponesimod to be approved as an oral treatment for adults with relapsing multiple sclerosis (MS). Ponesimod, formerly ACT-128800, is an experimental treatment that targets the protein sphingosine-1-phosphate…

Ponesimod may soon be a new oral therapy for people with relapsing multiple sclerosis (MS) in Europe, and a filing for its approval in the U.S. is likely within weeks. Janssen Pharmaceuticals, its developer, submitted an application to the European Medicines Agency (EMA) in early March, a first ponesimod filing…

Janssen has submitted an application to the European Medicines Agency (EMA) asking that ponesimod be approved as an oral treatment for adults with relapsing multiple sclerosis (MS) in the European Union. Ponesimod (formerly ACT-128800) is an experimental treatment that targets the sphingosine-1-phosphate receptor…

AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show. Masitinib, formerly known as AB1010, is an oral…

New data from Public Health England (PHE) and the U.K. MS Society show that the number of people with multiple sclerosis (MS) in the United Kingdom is now more than 130,000 — about one in every 500 people living in the country. This is an increase of…

Progressive cognitive decline in patients with multiple sclerosis (MS) may not be as inevitable as previously thought, a study suggests. The study, “A longitudinal study of cognitive function in multiple sclerosis: is decline inevitable?,” was published in the Journal of Neurology. Statistics indicate that some kind…

The agency in charge of health and social services for Quebec, known as the Institut national d’excellence en santé et en services sociaux (INESSS), is recommending that Mavenclad (cladribine) be offered at discount to adults with relapsing-remitting multiple sclerosis (RRMS) enrolled in the province’s health system. INESSS’ opinions…

The experimental BTK inhibitor SAR442168 showed an acceptable safety profile and met its primary endpoint — a significant reduction in the number of new lesions visible on a brain imaging scan — in a Phase 2 trial in people with multiple sclerosis (MS), study results show. SAR442168,…

The Multiple Sclerosis Association of America (MSAA) is celebrating 50 years of work and dedication to improving the lives of people affected by multiple sclerosis (MS). Some changes are underway and initiatives being launched to commemorate this milestone. MSAA, a nonprofit organization founded in 1970, aims to provide…

Caring for children with multiple sclerosis (MS) can affect the mental health of their mothers over the long term, a study has found. The study, “Increased mental health care use by mothers of children with multiple sclerosis,” was published in the journal Neurology. People with…

The National Institute for Health Care and Excellence (NICE) in the U.K. issued its final decision, approving the inclusion of Plegridy (peginterferon beta-1a) to treat relapsing-remitting multiple sclerosis (RRMS) in England within the National Health Service (NHS). This decision follows a cost-effectiveness review done in May 2018,…